Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia

This study is looking for adults aged 18 or older who have been recently diagnosed with Acute Myeloid Leukaemia (AML). This is specifically for people whose AML cannot be treated with strong, intensive chemotherapy, perhaps due to other health reasons or their overall fitness. It doesn't matter if your AML started on its own or developed after other conditions.

There are a few conditions that would mean you couldn't join. For example, if your AML has spread to your brain or spinal cord, or if you're able to have a stem cell transplant right now, this study wouldn't be suitable. Also, if you've recently had certain vaccines or have HIV, you wouldn't be able to take part. Researchers also need to make sure you don't have known allergies to any of the study medications or their ingredients.

Sometimes, to manage your condition before the study starts, you might have had certain initial treatments like hydroxyurea or very low-dose chemotherapy for a short time. This is generally OK, as long as these treatments were stopped at least 24 hours before you start the study drugs. The most important thing is that the research team will carefully check all your medical information to see if this study is the right fit for you.

If you decide to take part in this study, you will receive the new drug cusatuzumab along with either azacitidine or venetoclax, depending on what the study doctors decide is best for your specific situation. The study team will regularly monitor your health, perform blood tests, and ask you about how you are feeling to check for any side effects and to see how your body is responding to the treatment. The exact number of hospital visits, assessments, and the full duration of your participation will be carefully explained by the study team. You will be given detailed information about the study schedule before you make any decisions.